Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Demirci, Umut; Tufan, Gulnihal; Aktas, Bilge; Balakan, Ozan; ALACACIOĞLU, AHMET; DANE, FAYSAL; ENGİN, HÜSEYİN; Kaplan, M.; Gunaydin, Yusuf; Ozdemir, Nuriye; Unek, I.; Karaca, Halit; Akman, Tulay; Sonmez, Ozlem; Coskun, Ugur; HARPUTLUOĞLU, HAKAN; Sevinc, Alper; Tonyali, Onder; Buyukberber, Suleyman; BENEKLİ, MUSTAFA

doi:10.1007/s00432-013-1390-8

Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., DANE F., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.139, sa.5, ss.829-835, 2013 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 139 Sayı: 5
Basım Tarihi: 2013
Doi Numarası: 10.1007/s00432-013-1390-8
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.829-835
İnönü Üniversitesi Adresli: Evet

Özet

The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.